202 related articles for article (PubMed ID: 819704)
1. [Immunity against Mycobacterium, with special reference to the experiments using BCG cell wall].
Yamamoto K
Kekkaku; 1976 May; 51(5):155-7. PubMed ID: 819704
[No Abstract] [Full Text] [Related]
2. The cellular and molecular basis of immunity against mycobacterial diseases.
Colston MJ
Soc Appl Bacteriol Symp Ser; 1996; 25():33S-39S. PubMed ID: 8972118
[No Abstract] [Full Text] [Related]
3. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis.
Olsen AW; Brandt L; Agger EM; van Pinxteren LA; Andersen P
Scand J Immunol; 2004 Sep; 60(3):273-7. PubMed ID: 15320884
[TBL] [Abstract][Full Text] [Related]
4. Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guérin induce equal protection.
Mollenkopf HJ; Kursar M; Kaufmann SH
J Infect Dis; 2004 Aug; 190(3):588-97. PubMed ID: 15243936
[TBL] [Abstract][Full Text] [Related]
5. [The genetic regulation of host response to inoculation with Mycobacterium bovis (BCG) and Mycobacterium tuberculosis H37RV].
Nikonenko BV; Mezhlumova MB; Moroz AM
Biull Eksp Biol Med; 1990 Nov; 110(11):526-8. PubMed ID: 2128037
[TBL] [Abstract][Full Text] [Related]
6. Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination.
Flaherty DK; Vesosky B; Beamer GL; Stromberg P; Turner J
J Leukoc Biol; 2006 Dec; 80(6):1262-71. PubMed ID: 16968819
[TBL] [Abstract][Full Text] [Related]
7. [Immunogenicity of interleukin 12 and DNA vaccine prime-BCG boost against Mycobacterium tuberculosis].
Gao L; Bao L; Hao M; Zhang L; Qin ZF
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 39(4):535-9. PubMed ID: 18798487
[TBL] [Abstract][Full Text] [Related]
8. [Recent acquisitions on the behavior of macrophages in the acquired immunity against tuberculosis].
Joseph M; Voisin C
Arch Monaldi; 1972; 27(3):246-71. PubMed ID: 4219268
[No Abstract] [Full Text] [Related]
9. Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection.
Palendira U; Spratt JM; Britton WJ; Triccas JA
Vaccine; 2005 Feb; 23(14):1680-5. PubMed ID: 15705472
[TBL] [Abstract][Full Text] [Related]
10. [Study of immunobiological properties of specific immunomodulators of the adjuvant type in experimental tuberculosis].
Gorelova LA; Zemskova ZS; Panasek IA; Nekrasov AV; Puchkova NG; Moroz AM; Romanova RIu
Probl Tuberk; 1996; (3):46-7. PubMed ID: 8754882
[TBL] [Abstract][Full Text] [Related]
11. [Chemical structures and biological functions of mycobacterial cell walls with special reference to immunity against airborne infection by the strain M. tuberculosis H37Rv].
Ribi E; Azuma I; Meyer T; Parker R; Brehmer W; Yamamura Y
Bull Int Union Tuberc; 1974; 49(1):366-77. PubMed ID: 4219732
[No Abstract] [Full Text] [Related]
12. Effects of pretreatment of mice with BCG cell walls in saline on subsequent vaccination with BCG oil droplet vaccine.
Meyer TJ; Anacker RL; Ribi E
Cell Immunol; 1974 Oct; 14(1):52-65. PubMed ID: 4219589
[No Abstract] [Full Text] [Related]
13. Development of a Mycobacterium bovis intranasal challenge model in mice.
Logan KE; Gavier-Widen D; Hewinson RG; Hogarth PJ
Tuberculosis (Edinb); 2008 Sep; 88(5):437-43. PubMed ID: 18590980
[TBL] [Abstract][Full Text] [Related]
14. [Antituberculous immunity, with special reference to protection against tuberculosis in mice immunized with cell walls from BCG (author's transl)].
Yamamoto K
Kekkaku; 1976 Nov; 51(11):453-62. PubMed ID: 1011437
[No Abstract] [Full Text] [Related]
15. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC
Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523
[TBL] [Abstract][Full Text] [Related]
16. Cell wall lipids from Mycobacterium bovis BCG are inflammatory when inoculated within a gel matrix: characterization of a new model of the granulomatous response to mycobacterial components.
Rhoades ER; Geisel RE; Butcher BA; McDonough S; Russell DG
Tuberculosis (Edinb); 2005 May; 85(3):159-76. PubMed ID: 15850754
[TBL] [Abstract][Full Text] [Related]
17. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B
Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772
[TBL] [Abstract][Full Text] [Related]
18. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
[TBL] [Abstract][Full Text] [Related]
19. Protection of mice against Mycobacterium tuberculosis infection by immunization with aqueous fraction of Triton X-100-soluble cell wall proteins.
Jeon BY; Kim HJ; Kim SC; Jo EK; Park JK; Paik TH; Kim SJ; Cho SN
Scand J Immunol; 2008 Jan; 67(1):18-23. PubMed ID: 18021187
[TBL] [Abstract][Full Text] [Related]
20. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
